
## Navindra Persaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8773551/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Racialised people in clinical guideline panels. Lancet, The, 2022, 399, 139-140.	13.7	11
2	The commercialization of patient data in Canada: ethics, privacy and policy. Cmaj, 2022, 194, E95-E97.	2.0	4
3	Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO. BMJ Open, 2022, 12, e053349.	1.9	12
4	Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022, 27, 100305.	1.3	0
5	Essential tobacco dependence medicines in 137 countries. Addiction, 2021, 116, 1606-1609.	3.3	1
6	Essential diabetes medicines and health outcomes in 127 countries. Diabetes, Obesity and Metabolism, 2021, 23, 1121-1128.	4.4	2
7	Managing conflicts of interest in the development of health guidelines. Cmaj, 2021, 193, E49-E54.	2.0	31
8	Associations between essential medicines and health outcomes for cardiovascular disease. BMC Cardiovascular Disorders, 2021, 21, 151.	1.7	3
9	Effect of free distribution of medicines on the process of care for adult patients with type 1 and type 2 diabetes and hypertension: post hoc analysis of randomised controlled trial findings. BMJ Open, 2021, 11, e042046.	1.9	0
10	Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. PLoS Medicine, 2021, 18, e1003590.	8.4	9
11	Reporting of Sociodemographic Variables in Randomized Clinical Trials, 2014-2020. JAMA Network Open, 2021, 4, e2110700.	5.9	22
12	Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study. BMJ Open, 2021, 11, e045262.	1.9	6
13	Biologic medicine inclusion in 138 national essential medicines lists. Pediatric Rheumatology, 2021, 19, 140.	2.1	0
14	Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study. Lancet Infectious Diseases, The, 2021, 21, 1429-1440.	9.1	18
15	Cash transfer during the COVID-19 pandemic: a multicentre, randomised controlled trial. Family Medicine and Community Health, 2021, 9, e001452.	1.6	7
16	Effect on Treatment Adherence of Distributing Essential Medicines at No Charge. JAMA Internal Medicine, 2020, 180, 27.	5.1	41
17	William Osler: saint in a "White man's dominion― Cmaj, 2020, 192, E1414-E1416.	2.0	11
18	Improving opioid guideline adherence: evaluation of a multifaceted, theory-informed pilot intervention for family physicians. BMJ Open, 2020, 10, e032167.	1.9	5

Navindra Persaud

#	Article	IF	CITATIONS
19	Cow's Milk Fat Obesity pRevention Trial (CoMFORT): a primary care embedded randomised controlled trial protocol to determine the effect of cow's milk fat on child adiposity. BMJ Open, 2020, 10, e035241.	1.9	2
20	Evaluation of Pharmacy Model in a Trial of Free Essential Medicine Access. Journal of Primary Care and Community Health, 2020, 11, 215013272092393.	2.1	0
21	Relation between opioid consumption and inclusion of opioids in 137 national essential medicines lists. BMJ Clobal Health, 2020, 5, e003563.	4.7	18
22	Drivers of the opioid crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing. PLoS ONE, 2020, 15, e0227045.	2.5	35
23	A comparison of national essential medicines lists in the Americas. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2020, 44, 1.	1.1	5
24	Title is missing!. , 2020, 15, e0227045.		0
25	Title is missing!. , 2020, 15, e0227045.		0
26	Title is missing!. , 2020, 15, e0227045.		0
27	Title is missing!. , 2020, 15, e0227045.		0
28	Title is missing!. , 2020, 15, e0227045.		0
29	Title is missing!. , 2020, 15, e0227045.		0
30	Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists. PLoS ONE, 2019, 14, e0220781.	2.5	12
31	Reliability of routinely collected anthropometric measurements in primary care. BMC Medical Research Methodology, 2019, 19, 84.	3.1	30
32	Health outcomes related to the provision of free, tangible goods: A systematic review. PLoS ONE, 2019, 14, e0213845.	2.5	3
33	A national electronic health record for primary care. Cmaj, 2019, 191, E28-E29.	2.0	21
34	Exploring the experiences of people in Ontario, Canada who have trouble affording medicines: a qualitative concept mapping study. BMJ Open, 2019, 9, e033933.	1.9	10
35	Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders. Cmaj, 2019, 191, E1093-E1099.	2.0	5
36	Withdrawn medicines included in the essential medicines lists of 136 countries. PLoS ONE, 2019, 14, e0225429.	2.5	7

NAVINDRA PERSAUD

#	Article	IF	CITATIONS
37	Comparison of essential medicines lists in 137 countries. Bulletin of the World Health Organization, 2019, 97, 394-404C.	3.3	67
38	Integrating legal services with primary care: The Health Justice Program. Canadian Family Physician, 2019, 65, 246-248.	0.4	4
39	Medication coverage for lawmakers may worsen access for everyone else. Preventive Medicine, 2018, 108, 67-73.	3.4	0
40	Does exposure to simulated patient cases improve accuracy of clinicians' predictive value estimates of diagnostic test results? A within-subjects experiment at St Michael's Hospital, Toronto, Canada. BMJ Open, 2018, 8, e019241.	1.9	6
41	Development of a provisional essential medicines list for children in Canada: consensus process. CMAJ Open, 2018, 6, E146-E150.	2.4	1
42	Community members co-designing a trial of medication access. Cmaj, 2018, 190, S44-S45.	2.0	3
43	ldentifying top 10 primary care research priorities from international stakeholders using a modified Delphi method. PLoS ONE, 2018, 13, e0206096.	2.5	20
44	New generic pricing scheme maintains high prices and risks of shortages. Cmaj, 2018, 190, E410-E411.	2.0	5
45	Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis. PLoS ONE, 2018, 13, e0189978.	2.5	12
46	A comparison of the content and primary literature support for online medication information provided by Lexicomp and Wikipedia. Journal of the Medical Library Association: JMLA, 2018, 106, 352-360.	1.7	8
47	Fantastic idea:. Canadian Family Physician, 2018, 64, 98.	0.4	0
48	Will the new opioid guidelines harm more people than they help? No. Canadian Family Physician, 2018, 64, 102-104.	0.4	3
49	Dangerous ideas: Top 3 proposals presented at Family Medicine Forum. Canadian Family Physician, 2018, 64, 97-98.	0.4	1
50	Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada. Cmaj, 2017, 189, E295-E302.	2.0	24
51	Fatal overdoses involving hydromorphone and morphine among inpatients: a case series. CMAJ Open, 2017, 5, E184-E189.	2.4	9
52	Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial. BMJ Open, 2017, 7, e015686.	1.9	7
53	Search for unpublished data by systematic reviewers: an audit. BMJ Open, 2017, 7, e017737.	1.9	24
54	8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information. PLoS ONE, 2017, 12, e0167609.	2.5	11

NAVINDRA PERSAUD

#	Article	IF	CITATIONS
55	Development of a preliminary essential medicines list for Canada. CMAJ Open, 2017, 5, E137-E143.	2.4	17
56	Canadian list of essential medications: Potential and uncertainties. Canadian Family Physician, 2017, 63, 266-268.	0.4	5
57	Why Clinicians Prognosticate Stroke Patients Poorly: Results from the Clinician Judgment versus Risk Score to Predict Stroke Outcomes Randomized Study. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1349-1354.	1.6	4
58	Toward better prescription drug surveillance in Canada. Cmaj, 2016, 188, E252-E253.	2.0	5
59	Drug Toxicity Deaths after Release from Incarceration in Ontario, 2006-2013: Review of Coroner's Cases. PLoS ONE, 2016, 11, e0157512.	2.5	36
60	North American regulatory agencies can and should make clinical trial data publicly available. Cmaj, 2016, 188, 96-97.	2.0	8
61	Using a systematic review in clinical decision making: a pilot parallel, randomized controlled trial. Implementation Science, 2015, 10, 118.	6.9	7
62	Characteristics of patients receiving long-term opioid therapy for chronic noncancer pain: a cross-sectional survey of patients attending the Pain Management Centre at Hamilton General Hospital, Hamilton, Ontario. CMAJ Open, 2015, 3, E324-E330.	2.4	18
63	How Can Journals Respond to Threats of Libel Litigation?. PLoS Medicine, 2014, 11, e1001615.	8.4	3
64	Questionable content of an industry-supported medical school lecture series: a case study. Journal of Medical Ethics, 2014, 40, 414-418.	1.8	32
65	Demonstrations of subconscious processing with the binary exclusion task. Behavioral and Brain Sciences, 2014, 37, 37-37.	0.7	3
66	Investigating pharmaceutical marketing in Canada using American prosecutions. International Journal of Risk and Safety in Medicine, 2014, 26, 147-153.	0.6	0
67	Should Doxylamine-Pyridoxine Be Used for Nausea and Vomiting of Pregnancy?. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 343-348.	0.7	15
68	Differences in the Volume of Pharmaceutical Advertisements between Print General Medical Journals. PLoS ONE, 2014, 9, e84790.	2.5	9
69	Development of two shortened systematic review formats for clinicians. Implementation Science, 2013, 8, 68.	6.9	9
70	Technology use by physicians and their impersonators. Cmaj, 2012, 184, 2024-2024.	2.0	1
71	Nonuse of bicycle helmets and risk of fatal head injury: a proportional mortality, case–control study. Cmaj, 2012, 184, E921-E923.	2.0	58
72	Epidemiological evidence in forensic pharmacovigilance. International Journal of Risk and Safety in Medicine, 2012, 24, 31-35.	0.6	6

NAVINDRA PERSAUD

#	Article	IF	CITATIONS
73	Awareness-related activity in prefrontal and parietal cortices in blindsight reflects more than superior visual performance. Neurolmage, 2011, 58, 605-611.	4.2	57
74	Direct assessment of qualia in a blindsight participant. Consciousness and Cognition, 2008, 17, 1046-1049.	1.5	21
75	Wagering demonstrates subconscious processing in a binary exclusion task. Consciousness and Cognition, 2008, 17, 565-575.	1.5	31
76	Commentary to Note by Seth: Experiments show what post-decision wagering measures. Consciousness and Cognition, 2008, 17, 984-985.	1.5	5
77	Blindsight is unlike normal conscious vision: Evidence from an exclusion task. Consciousness and Cognition, 2008, 17, 1050-1055.	1.5	34
78	How can I tell how I think till I see what I say?. Consciousness and Cognition, 2008, 17, 1375.	1.5	2
79	Broken telephone in the brain: The need for metacognitive measures. Behavioral and Brain Sciences, 2007, 30, 513-514.	0.7	0
80	Post-decision wagering objectively measures awareness. Nature Neuroscience, 2007, 10, 257-261.	14.8	417
81	External validity: the neglected dimension in evidence ranking. Journal of Evaluation in Clinical Practice, 2006, 12, 450-453.	1.8	47